Interaction between fluconazole and midazolam in intensive care patients

Acta Anaesthesiologica Scandinavica

Volumn 43, Issue 5, 1999, Pages 509-514

  Ahonen, Jouni ^a   Olkkola, K T ^a   Takala, A ^a   Neuvonen, P J ^a  

^a NONE

Author keywords

Fluconazole; Intensive care; Interaction; Midazolam; Sedation

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; FLUCONAZOLE; MIDAZOLAM;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; FEMALE; HUMAN; INTENSIVE CARE; INTRAVENOUS DRUG ADMINISTRATION; LIVER FUNCTION; LIVER PERFUSION; MALE; PRIORITY JOURNAL; SEDATION;

ADULT; ANALYSIS OF VARIANCE; ANTIFUNGAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; FLUCONAZOLE; FOLLOW-UP STUDIES; HUMANS; HYPNOTICS AND SEDATIVES; INFUSIONS, INTRAVENOUS; INTENSIVE CARE; KIDNEY FAILURE; MALE; MIDAZOLAM; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POSITIVE-PRESSURE RESPIRATION;

EID: 0032901327     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-6576.1999.430504.x     Document Type: Article

References (25)

1. Beck-Sague CM, Jarvis WR. National Nosocomial Infections Surveillance System. Secular trends in epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993: 167: 1247-1251.
2. Vincent JL, Bihari DJ, Suter FM, Bruining HA, White J, Nicolas-Chanoin MH et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European prevalence of infection in intensive care (EPIC) study. JAMA 1995: 274: 639-644.
3. Lipman J, Saadia R. Fungal infections in critically ill patients. BMJ 1997: 315: 266-267.
4. Nguyen MH, Peacock JE, Tanner DC, Morris AJ, Nguyen ML, Snydman DR et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter prospective observational study. Arch Intern Med 1995: 155: 2429-2435.
5. Wandel C, Böcker R, Böhrer H, Browne A, Rügheimer E, Martin E. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 1994: 73: 658-661.
6. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg J-J et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993: 53: 298-305.
7. Backman JT, Olkkola KT, Aranko K, Himberg J-J, Neuvonen PJ. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994: 37: 221-225.
8. Olkkola KT, Backman J, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994: 55: 481-485.
9. Olkkola KT, Ahonen J, Neuvonen PJ. Effect of the systemic antimycotics itraconazole and fluconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996: 82: 511-516.
10. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 1997: 51: 415-419.
11. Gaillard Y, Gay-Montchamp J-P, Ollagnier M. Simultaneous screening and quantitation of alpidem, zolpidem, buspirone, and benzodiazepines by dual-channel gas chromatography using electron-capture and nitrogen-phosphorous detection after solid-phase extraction. J Chromatogr 1993: 622: 197-208.
12. Vree TB, Baars AM, Booij LHD, Driessen JJ. Simultaneous determination and pharmacokinetics of midazolam and its hydroxymetabolites in plasma and urine of man and dog by means of high-performance liquid chromatography. Arztneimittelforschung/Drug Research 1981: 31: 2215-2219.
13. Sunzel M. Determination of midazolam and the α-hydroxy metabolite by gas chromatography in small plasma volumes. J Chromatogr 1989: 491: 455-460.
14. Dirksen M, Vree T, Driessen J. Midazolam in the intensive care unit. Drug Intell Clin Pharm 1986: 20: 805-806.
15. Malacrida R, Fritz ME, Suter PM, Crevoicier C. Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients. Crit Care Med 1991: 20: 1123-1126.
16. Maitre PO, Funk B, Crevoisier C, Ha HR. Pharmacokinetics of midazolam in patients recovering from cardiac surgery. Eur J Clin Pharmacol 1989: 37: 161-166.
17. Shelly MP, Mendel L, Park GR. Failure of critically ill patients to metabolize midazolam. Anaesthesia 1987: 42: 619-626.
18. Malacrida R, Fritz ME, Suter PM, Crevoisier C. Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients. Crit Care Med 1992: 20: 1123-1126.
19. Park GR, Miller E. What changes drug metabolism in critically ill patients - III? Effect of pre-existing disease on the metabolism of midazolam. Anaesthesia 1996: 51: 431-434.
20. Pentikäinen PJ, Välisalmi L, Himberg JJ, Crevoicier C. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol 1989: 29: 272-277.
21. Trouvin JH, Farinotti R, Haberer JP, Servin F, Chauvin M, Duvaldestin P. Pharmacokinetics of midazolam in anaesthetized cirrhotic patients. Br J Anaesth 1988: 60: 762-767.
22. Rinetti M, Ascalone V, Colombi Zinelli L, Cisternino M. A pharmacokinetic study on midazolam in compensated liver cirrhosis. Int J Clin Pharmacol Res 1985: 5: 405-411.
23. Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clin Pharmacol Ther 1981: 30: 653-661.
24. Hase I, Oda Y, Tanaka K, Mizutani K, Nakamoto T, Asada A. I.v. fentanyl decreases the clearance of midazolam. Br J Anaesth 1997: 79: 740-743.
25. Bauer TM, Ritz R, Haberthür C, Ha HR, Hunkeler W, Sleight AJ et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995: 346: 145-147.